Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px
Organisation › Details

MiNA Therapeutics Ltd.

Harnessing the innate mechanism of gene activation, MiNA Therapeutics’ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver diseases. MiNA Therapeutics was founded in 2008 to capitalise on the breakthrough discovery of small activating RNAs and to build a platform technology that enables the development of new medicines that restore normal function to patients’ cells. The Company has an extensive intellectual property portfolio and to date has been financed by angel investors and high-net-worth individuals. MiNA’s lead clinical asset, MTL-CEBPA, is the first development candidate to emerge from its unique RNA activation platform, which is being applied to design and develop saRNA therapeutics to activate key genes to treat a broad range of diseases. *

 

Period Start 2008-03-07 established
Product Industry small activating RNA therapeutic (saRNA)
Persons Person Habib, Robert (MiNA Therapeutics Ltd 201705 CEO)
  Person 2 Bains, Peter (MiNA Therapeutics 202009– CBO before Sosei Heptares + Biocon/Syngene International + GSK)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 80 Wood Lane
Translation & Innovation Hub, ICL White City Campus
  City W12 0BZ London
  Tel +44-208-811-6700
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: MiNA Therapeutics Ltd.. (5/3/17). "Press Release: Sosei Pays GBP 35 Million for an Equity Stake and Acquisition Option Agreement in MiNA Therapeutics". Tokyo & London.
     
   
Record changed: 2021-01-24

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for MiNA Therapeutics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top